Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary

NovoCure

23/07/2026 14:31

Novocure Ltd NVCR.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -36 cents.  The mean expectation of six analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -40 cents to -23 cents per share.
Revenue rose 15.6% to $183.58 million from a year ago; analysts expected $172.44 million. 
Novocure Ltd's reported EPS for the quarter was a loss of 13 cents​.
The company reported a quarterly loss of $15.66 million.
Novocure Ltd shares had risen by 2.8% this quarter and gained 20.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 10% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" 
Wall Street's median 12-month price target for Novocure Ltd is $23.50, about 33.7% above its last closing price of $15.57
This summary was machine generated from LSEG data July 23 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.33
-0.17
Beat
Mar. 31 2026 
-0.51
-0.62
Missed
Dec. 31 2025 
-0.41
-0.22
Beat
Sep. 30 2025 
-0.42
-0.33
Beat